At a WTP threshold of $12,728 per QALY, 4 subgroups were associated with positive ICER and > 50% probability of being cost-effective, namely, patients older than 65 years old, ECOG performance status score equals to 1, disease stage IIIB/IIIC and PD-L1 tumor proportion score ≤ 1%. The gene discussed is CD274; the disease is neoplasm.